These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17567869)

  • 1. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study.
    Isaacs KL; Sandler RS; Abreu M; Picco MF; Hanauer SB; Bickston SJ; Present D; Farraye FA; Wolf D; Sandborn WJ;
    Inflamm Bowel Dis; 2007 Oct; 13(10):1250-5. PubMed ID: 17567869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis.
    Shen B; Pardi DS; Bennett AE; Queener E; Kammer P; Hammel JP; LaPlaca C; Harris MS
    Am J Gastroenterol; 2009 Jun; 104(6):1468-74. PubMed ID: 19436282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis.
    Abdelrazeq AS; Kelly SM; Lund JN; Leveson SH
    Colorectal Dis; 2005 Mar; 7(2):182-6. PubMed ID: 15720360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis.
    Gionchetti P; Rizzello F; Venturi A; Ugolini F; Rossi M; Brigidi P; Johansson R; Ferrieri A; Poggioli G; Campieri M
    Aliment Pharmacol Ther; 1999 Jun; 13(6):713-8. PubMed ID: 10383499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.
    Prantera C; Lochs H; Grimaldi M; Danese S; Scribano ML; Gionchetti P;
    Gastroenterology; 2012 Mar; 142(3):473-481.e4. PubMed ID: 22155172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab for the Treatment of Chronic Pouchitis.
    Travis S; Silverberg MS; Danese S; Gionchetti P; Löwenberg M; Jairath V; Feagan BG; Bressler B; Ferrante M; Hart A; Lindner D; Escher A; Jones S; Shen B;
    N Engl J Med; 2023 Mar; 388(13):1191-1200. PubMed ID: 36988594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis.
    Shen B; Remzi FH; Lopez AR; Queener E
    BMC Gastroenterol; 2008 Jun; 8():26. PubMed ID: 18573211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
    Holubar SD; Cima RR; Sandborn WJ; Pardi DS
    Cochrane Database Syst Rev; 2010 Jun; (6):CD001176. PubMed ID: 20556748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis.
    Miner P; Wedel M; Bane B; Bradley J
    Aliment Pharmacol Ther; 2004 Feb; 19(3):281-6. PubMed ID: 14984374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season.
    Flores J; Dupont HL; Jiang ZD; Okhuysen PC; Melendez-Romero JH; Gonzalez-Estrada A; Carrillo I; Paredes M
    J Travel Med; 2011; 18(5):333-6. PubMed ID: 21896097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.
    Prantera C; Lochs H; Campieri M; Scribano ML; Sturniolo GC; Castiglione F; Cottone M
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1117-25. PubMed ID: 16611272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial.
    Kjær MD; Qvist N; Nordgaard-Lassen I; Christensen LA; Kjeldsen J
    Scand J Gastroenterol; 2019 Feb; 54(2):188-193. PubMed ID: 30739519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral beclomethasone dipropionate in chronic refractory pouchitis.
    Gionchetti P; Calabrese C; Calafiore A; Praticò C; Poggioli G; Laureti S; Capozzi N; Campieri M; Rizzello F
    J Crohns Colitis; 2014 Jul; 8(7):649-53. PubMed ID: 24394806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis.
    Shen B; Achkar JP; Lashner BA; Ormsby AH; Remzi FH; Brzezinski A; Bevins CL; Bambrick ML; Seidner DL; Fazio VW
    Inflamm Bowel Dis; 2001 Nov; 7(4):301-5. PubMed ID: 11720319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacotherapy for inducing and maintaining remission in pouchitis.
    Sandborn W; McLeod R; Jewell D
    Cochrane Database Syst Rev; 2000; (2):CD001176. PubMed ID: 10796613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical therapy for induction and maintenance of remission in pouchitis: a systematic review.
    Sandborn WJ; McLeod R; Jewell DP
    Inflamm Bowel Dis; 1999 Feb; 5(1):33-9. PubMed ID: 10028447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.
    Pimentel M; Park S; Mirocha J; Kane SV; Kong Y
    Ann Intern Med; 2006 Oct; 145(8):557-63. PubMed ID: 17043337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.
    Garey KW; Ghantoji SS; Shah DN; Habib M; Arora V; Jiang ZD; DuPont HL
    J Antimicrob Chemother; 2011 Dec; 66(12):2850-5. PubMed ID: 21948965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of rifaximin in prevention of diarrhoea in individuals travelling to south and southeast Asia: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zanger P; Nurjadi D; Gabor J; Gaile M; Kremsner PG
    Lancet Infect Dis; 2013 Nov; 13(11):946-54. PubMed ID: 24012319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.
    Rivkin A; Rybalov S
    Pharmacotherapy; 2016 Mar; 36(3):300-16. PubMed ID: 26971716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.